Antiplatelet monoclonal autoantibodies (mAbs) were derived from CBA mice immunized with rat platelets. Two IgM antiplatelet mAbs were further analyzed. L1C43 mAb bound a 150–160 kDa antigen, recognized activated platelets better than resting ones and impaired platelet adhesion, but not clot retraction. L1H31 mAb recognized a ±95 kDa molecule, bound similarly activated and resting platelets and did not modify platelet adhesion, but inhibited clot retraction. Both mAbs induced in vivo thrombocytopenia most likely through phagocytosis of opsonized platelets. These autoreactive antibodies can thus induce both platelet destruction and impairment of their function. They are reflective of autoantibodies found in human patients and may serve for further analysis of antiplatelet autoantibody pathogenicity and mechanisms of autoimmune disease.
MusajiA, VanhoorelbekeK, DeckmynH, CoutelierJ-P. New model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets. Exp Hematol2004;32:87–94
2.
LengweilerS, SmythSS, JirouskovaM, ScudderLE, ParkH, MoranT, CollerBS. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (aIIbb3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun1999;262:167–73
3.
ChenP, SunC-X, LiuJ-N. A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin aIIbb3 inhibits platelet aggregation and adhesion. J Biol Chem2005;280:25403–8
4.
MizutaniH, EngelmanRW, KurataY, IkeharaS, GoodRA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW X BXSB)F1 mice. Blood1993;82:837–44
5.
NimmerjahnF, RavetchJV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science2005;310:1510–2
6.
AlbertH, CollinM, DudziakD, RavetchJV, NimmerjahnF. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci USA2008;105:15005–9
7.
van RooijenN. The liposome-mediated macrophage ‘suicide’ technique. J Immunol Methods1989;124:1–6
8.
ShenkmanB, SavionN, DardikR, TamarinI, VaronD. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res2000;99:353–61
9.
SavionN, VaronD. Impact – the cone and plate(let) analyzer: testing platelet function and anti-platelet drug response. Pathophysiol Haemost Thromb2006;35:83–8
10.
van RooijenN, SandersA. Liposome-mediated depletion of macrophages – mechanism of action, preparation of liposomes and applications. J Immunol Methods1994;174:89–93
11.
LeenenPJM, RadosevicK, VoermanJSA, SalomonB, van RooijenN, KlatzmannD, van EwijkW. Heterogeneity of mouse spleen dendritic cells: In vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol1998;160:2166–73
12.
JiangN, ReichCF, PisetskyDS. Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood2003;102:2243–50
13.
JordanMB, van RooijenN, IzuiS, KapplerJ, MarrackP. Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood2003;101:594–601
14.
MusajiA, CormontF, ThirionG, CambiasoCL, CoutelierJ-P. Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. Blood2004;104:2102–6
15.
Alves-RosaF, StanganelliC, CabreraJ, van RooijenN, PalermoMS, IsturizMA. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood2000;96:2834–40
16.
Alves-RosaF, StanganelliC, CabreraJ, CymberknopD, RubelC, VanzulliS, van RooijenN. Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia. Br J Haematol2002;116:357–66
17.
OsdoitS, RosaJ-P. Fibrin clot retraction by human platelets correlates with aIIbb3integrin-dependent protein tyrosine dephosphorylation. J Biol Chem2001;276:6703–10
18.
SchmitzG, RotheG, RufA, BarlageS, TschöpeD, ClemetsonKJ, GoodallAH, MichelsonAD, NurdenAT, ShankeyTV. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost1998;79:885–96
19.
NieswandtB, BergmeierW, RackebrandtK, GessnerJE, ZirngiblH. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood2000;96:2520–7
20.
FuM, FanPS, LiW, LiCX, XingY, AnJG, WangG, FanXL, GaoTW, LiuYF, IkedaS. Identification of poly-reactive natural IgM antibody that recognizes late apoptotic cells and promotes phagocytosis of the cells. Apoptosis2007;12:355–62
21.
ChenYF, ParkYB, PatelE, SilvermanGJ. IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells. J Immunol2009;182:6031–43
22.
SubramaniamKS, DattaK, QuinteroE, ManixC, MarksMS, PirofskiLA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J Immunol2010;184:5755–67
StahlD, HoembergM, CassensU, PachmannU, SibrowskiW. Evidence that human autoimmune thrombocytopenia mediated by both immunoglobulin isotypes IgM and IgG is an independent disease entity. Eur J Haematol2005;75:318–27
